Clinical Imaging Research Centre (CIRC) at NUS Medicine and Cyclotek to strengthen radiopharmaceutical capability in Singapore and across ASEAN
Published: 05 Dec 2025
(Left) Mr Jon Evans, CEO of Cyclotek International and (right) Prof Pek-Lan Khong, Director of the Clinical Imaging Research Centre (CIRC) at a collaborative agreement signing event on 2 December 2025.
NUS Medicine’s Clinical Imaging Research Centre (CIRC), a leading academic centre for advanced molecular imaging, and Cyclotek, one of Australia and New Zealand’s premier radiopharmaceutical manufacturers and distributors, announced on 2 December 2025 a strategic collaboration to enhance radiopharmaceutical development, clinical trials, and precision diagnostic capability across Singapore and the wider ASEAN region.
The partnership brings together CIRC’s imaging and clinical trial research experience with Cyclotek’s established manufacturing network, GMP and CDMO capabilities. Together, the organisations aim to create a stronger, more connected, and innovation-ready radiopharmaceutical ecosystem that can deliver earlier diagnosis, more accurate disease characterisation, and improved access to next-generation diagnostic and therapeutic agents.
The collaboration will explore opportunities to:
- Increase access to Investigational Medicinal Products (IMPs) for clinical trials in Singapore and ASEAN
- Strengthen regional supply resilience for emerging diagnostic and radioligand therapy products
- Evaluate and translate promising radiopharmaceuticals from research settings into clinical practice
- Expand opportunities for cross-border clinical trials and translational research
Professor Pek-Lan Khong, Director of the Clinical Imaging Research Centre (CIRC) and Provost’s Chair, Department of Diagnostic Radiology, at NUS Medicine, said: This collaboration is a strategic imperative for biomedical innovation in Singapore. By exploring how our research capabilities and clinical trial infrastructure can be combined with Cyclotek’s advanced manufacturing network, we hope to create a powerful conduit to accelerate promising new radiopharmaceutical research from our Academic GMP Cyclotron facility to clinical trials in Singapore and the ASEAN region, and finally, translating it into clinical practice for the benefit of patients. This effort will not only elevate the standard of patient care but also foster co- investment in grant-focused research and build a talent pipeline through specialized training programmes.”
Mr Jon Evans, CEO of Cyclotek International, said: “Cyclotek is deeply committed to ensuring reliable, high-quality access to life-changing radiopharmaceuticals. Our partnership with NUS CIRC is foundational to realising this vision in Southeast Asia. This joint effort aims to increase the utility and availability of these products for hospitals, clinicians, and patients across the ASEAN health and economic community, supporting next-generation molecular imaging and therapy essential for individualised diagnosis and treatment of serious diseases. This is a compelling value proposition that reduces long-term social and economic costs.”
As the collaboration develops, both organisations will also explore future opportunities to support talent development and specialised training in radiopharmaceutical science and advanced molecular imaging, strengthening the long-term workforce capabilities essential for a sustainable regional ecosystem.
The partnership is expected to increase access to PET radiopharmaceuticals for clinical research, support evaluation of emerging diagnostic and therapeutic agents, and improve supply reliability for investigational products. This will aid the earlier detection and characterisation of cancer, neurological diseases, and other serious conditions, contributing to better patient outcomes and improved health system resilience across ASEAN.
